Third Harmonic Bio

Third Harmonic Bio is advancing a novel therapeutic strategy focused on selectively inhibiting the KIT receptor, the master regulator of mast cells, to address severe allergic and inflammatory conditions. Its lead asset, THB001, is in Phase 1b development for chronic urticaria, with a preclinical program, THB222, targeting fibrosis via DDR1 inhibition. The company's strategy is to leverage its targeted platform to develop oral therapies with superior safety profiles for chronic use, aiming to capture significant value in large immunology markets. Having gone public in 2022, Third Harmonic operates as a focused, lean organization advancing its pipeline through key clinical milestones.

Platform for developing highly selective, oral small-molecule kinase inhibitors, initially focused on KIT for mast cell-driven diseases and DDR1 for fibrosis, designed for chronic use with optimized safety profiles.

Competes against injectable biologics (e.g., omalizumab) and other oral agents in development for urticaria. Key differentiation is THB001's oral route and direct mast cell depletion mechanism. In fibrosis, THB222 would enter a crowded field against approved and investigational therapies.